BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05686044 (Buntanetap/Posiphen in Alzheimer Disease): BVCT ex-ante prediction vs. reported outcome

On 24 Mar 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 29 Apr 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05686044
Drug Name
Buntanetap/Posiphen
Drug MoA
neurotoxic protein synthesis inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Alzheimer Disease
Human Patients
320
Sponsor
Annovis Bio
Phase
Phase 2 Phase 3

Prediction of , index 935

Prospective Prediction
Prediction Index
935
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically maybe significant yet very weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
36 days in advance
Readout Data Interpretation
key efficacy endpoints ADAS-COG11; ADCS-CGIC; ADCS-ADL not met.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Buntanetap in Participants With Mild to Moderate Alzheimer's Disease
Phase
Phase 2, Phase 3
Status
Completed
Enrollment
351
Lead sponsor
Annovis Bio Inc.
Conditions
Alzheimer Disease
Interventions
DRUG: Buntanetap/Posiphen; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-04-01
Primary completion
2024-02-13
Completion
2024-02-13
Results first posted
2025-04-29
Primary outcomes
  • Change From Baseline to Week 12 in ADAS-Cog11 (Baseline to the end of treatment period (12 weeks))
  • ADCS-CGIC at Week 12 (Baseline to the end of treatment period (12 weeks))

NCT05686044 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials